• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肝细胞癌的经皮治疗：肝脏定向治疗的演变

Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies.

作者信息

Huber Timothy C, Bochnakova Teodora, Koethe Yilun, Park Brian, Farsad Khashayar

机构信息

Dotter Department of Interventional Radiology, Oregon Health and Science University, Portland, OR, USA.

出版信息

J Hepatocell Carcinoma. 2021 Sep 23;8:1181-1193. doi: 10.2147/JHC.S268300. eCollection 2021.

DOI:10.2147/JHC.S268300
PMID:34589446
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8476177/
Abstract

Percutaneous ablation is a mainstay of treatment for early stage, unresectable hepatocellular carcinoma (HCC). Recent advances in technology have created multiple ablative modalities for treatment of this common malignancy. The purpose of this review is to familiarize readers with the technical and clinical aspects of both existing and emerging percutaneous treatment options for HCC.

摘要

经皮消融是早期不可切除肝细胞癌（HCC）治疗的主要手段。技术的最新进展为这种常见恶性肿瘤的治疗创造了多种消融方式。本综述的目的是让读者熟悉现有和新兴的HCC经皮治疗方案的技术和临床方面。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/311f/8476177/e74fb6ce1124/JHC-8-1181-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/311f/8476177/ed95e742f682/JHC-8-1181-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/311f/8476177/e74fb6ce1124/JHC-8-1181-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/311f/8476177/ed95e742f682/JHC-8-1181-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/311f/8476177/e74fb6ce1124/JHC-8-1181-g0002.jpg

相似文献

1
Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies.肝细胞癌的经皮治疗：肝脏定向治疗的演变
J Hepatocell Carcinoma. 2021 Sep 23;8:1181-1193. doi: 10.2147/JHC.S268300. eCollection 2021.
2
The Role of Ablative Techniques in the Management of Hepatocellular Carcinoma: Indications and Outcomes.消融技术在肝细胞癌治疗中的作用：适应证与治疗结果
Biomedicines. 2023 Mar 31;11(4):1062. doi: 10.3390/biomedicines11041062.
3
What's New in Percutaneous Ablative Strategies for Hepatocellular Carcinoma and Colorectal Hepatic Metastases? 2020 Update.经皮消融治疗肝细胞癌和结直肠癌肝转移的新进展：2020 年更新。
Curr Oncol Rep. 2020 Jul 28;22(10):105. doi: 10.1007/s11912-020-00967-y.
4
Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.肝细胞癌的局部区域治疗：外科医生视角的批判性综述
Ann Surg. 2002 Apr;235(4):466-86. doi: 10.1097/00000658-200204000-00004.
5
Technology insight: Image-guided therapies for hepatocellular carcinoma--intra-arterial and ablative techniques.技术洞察：肝细胞癌的图像引导治疗——动脉内和消融技术。
Nat Clin Pract Oncol. 2006 Jun;3(6):315-24. doi: 10.1038/ncponc0512.
6
State of the ablation nation: a review of ablative therapies for cure in the treatment of hepatocellular carcinoma.消融治疗肝癌的现状：根治性消融治疗的综述。
Future Oncol. 2017 Jul;13(16):1437-1448. doi: 10.2217/fon-2017-0061. Epub 2017 Jul 7.
7
Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.经皮治疗肝细胞癌：现状与创新。
J Hepatol. 2018 Apr;68(4):783-797. doi: 10.1016/j.jhep.2017.10.004. Epub 2017 Oct 13.
8
Percutaneous Ablation for Hepatocellular Carcinoma.经皮消融治疗肝细胞癌。
AJR Am J Roentgenol. 2018 Jun;210(6):1368-1375. doi: 10.2214/AJR.17.18695. Epub 2018 Apr 27.
9
Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review.经动脉化疗栓塞联合射频或微波消融治疗肝细胞癌：综述
Hepat Oncol. 2018 Sep 28;5(2):HEP07. doi: 10.2217/hep-2018-0001. eCollection 2018 Apr.
10
Thermal ablation for hepatocellular carcinoma: what's new in 2019.肝细胞癌的热消融：2019年有哪些新进展。
Chin Clin Oncol. 2019 Dec;8(6):58. doi: 10.21037/cco.2019.11.03.

引用本文的文献

1
Targeting inflammatory pathways in hepatocellular carcinoma: recent developments.肝细胞癌中炎症通路的靶向治疗：最新进展
Discov Oncol. 2025 Jun 22;16(1):1174. doi: 10.1007/s12672-025-03035-8.
2
Augmented Reality for Surgical Navigation: A Review of Advanced Needle Guidance Systems for Percutaneous Tumor Ablation.用于手术导航的增强现实：经皮肿瘤消融高级针引导系统综述
Radiol Imaging Cancer. 2025 Jan;7(1):e230154. doi: 10.1148/rycan.230154.
3
Anti-tumor efficacy of : Suppressing liver cancer by targeting tumor-associated macrophages.

本文引用的文献

1
A review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis.关于射频、微波及高强度聚焦超声消融治疗肝硬化肝细胞癌的综述
Hepatobiliary Surg Nutr. 2021 Apr;10(2):193-209. doi: 10.21037/hbsn.2020.03.11.
2
Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma.切换单极射频消融可改善中等大小肝癌的长期疗效。
Eur Radiol. 2021 Nov;31(11):8649-8661. doi: 10.1007/s00330-021-07729-9. Epub 2021 Apr 25.
3
Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.
靶向肿瘤相关巨噬细胞抑制肝癌的抗肿瘤疗效。
World J Gastroenterol. 2024 Oct 14;30(38):4249-4253. doi: 10.3748/wjg.v30.i38.4249.
4
Threatment Strategies for Recurrent Hepatocellular Carcinoma Patients: Ablation and its Combination Patterns.复发性肝细胞癌患者的治疗策略：消融及其联合模式。
J Cancer. 2024 Feb 25;15(8):2193-2205. doi: 10.7150/jca.93885. eCollection 2024.
5
Matrin-3 acts as a potential biomarker and promotes hepatocellular carcinoma progression by interacting with cell cycle-regulating genes.Matrin-3 作为一种潜在的生物标志物，通过与细胞周期调节基因相互作用促进肝癌的进展。
Cell Cycle. 2024 Jan;23(1):15-35. doi: 10.1080/15384101.2024.2305535. Epub 2024 Jan 22.
6
PD1 and TIM3 Expression is Associated with Very Early Hepatocellular Carcinoma Recurrence After Percutaneous Thermal Ablation.程序性死亡蛋白1（PD1）和T细胞免疫球蛋白黏蛋白3（TIM3）表达与经皮热消融术后极早期肝细胞癌复发相关。
J Hepatocell Carcinoma. 2024 Jan 9;11:39-50. doi: 10.2147/JHC.S443134. eCollection 2024.
7
The Effect of Cooling Fluid Composition on Ablation Size in Hepatic Laser Ablation: A Comparative Study in an Ex Vivo Bovine Setting.冷却液成分对肝激光消融消融大小的影响：牛离体模型的对比研究。
Tomography. 2023 Sep 1;9(5):1638-1648. doi: 10.3390/tomography9050131.
8
Nationwide Trends and the Influence of Age and Gender in the In-Patient Care of Patients with Hepatocellular Carcinoma in Germany between 2010 and 2020.2010年至2020年间德国肝细胞癌患者住院治疗的全国趋势以及年龄和性别的影响
Cancers (Basel). 2023 May 17;15(10):2792. doi: 10.3390/cancers15102792.
9
Quantitative Dual-Energy CT Image Guidance for Thermochemical Ablation: In Vivo Results in the Rabbit VX2 Model.定量双能 CT 图像引导的热化学消融：兔 VX2 模型的体内结果。
J Vasc Interv Radiol. 2023 May;34(5):782-789. doi: 10.1016/j.jvir.2022.12.026. Epub 2022 Dec 17.
10
Local-Regional Treatment of Hepatocellular Carcinoma: A Primer for Radiologists.肝细胞癌的局部区域治疗：放射科医生的入门指南。
Radiographics. 2022 Oct;42(6):1670-1689. doi: 10.1148/rg.220022.
索拉非尼纳米颗粒递送系统在肝细胞癌治疗中的现状
Theranostics. 2021 Mar 13;11(11):5464-5490. doi: 10.7150/thno.54822. eCollection 2021.
4
Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis.经导管动脉化疗栓塞术与射频消融术单独或联合治疗肝细胞癌：一项事件时间的荟萃分析
World J Surg Oncol. 2021 Mar 19;19(1):81. doi: 10.1186/s12957-021-02188-4.
5
Relationship of Antenna Work and Ablation Cavity Volume Following Percutaneous Microwave Ablation of Hepatic Tumors.经皮微波消融治疗肝肿瘤后天线工作与消融腔体积的关系。
J Vasc Interv Radiol. 2021 Apr;32(4):536-543. doi: 10.1016/j.jvir.2020.12.012. Epub 2021 Feb 4.
6
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.局部区域治疗在肝癌的分子和免疫治疗时代。
Nat Rev Gastroenterol Hepatol. 2021 May;18(5):293-313. doi: 10.1038/s41575-020-00395-0. Epub 2021 Jan 28.
7
Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure.晚期肝细胞癌的局部区域与全身联合治疗：最终，前景仍不明朗。
Ann Transl Med. 2020 Dec;8(24):1700. doi: 10.21037/atm-20-4164.
8
Comparison of Smartphone Augmented Reality, Smartglasses Augmented Reality, and 3D CBCT-guided Fluoroscopy Navigation for Percutaneous Needle Insertion: A Phantom Study.智能手机增强现实、智能眼镜增强现实和 3D CBCT 引导透视导航在经皮穿刺针插入中的比较：一项体模研究。
Cardiovasc Intervent Radiol. 2021 May;44(5):774-781. doi: 10.1007/s00270-020-02760-7. Epub 2021 Jan 6.
9
Augmented reality improves procedural efficiency and reduces radiation dose for CT-guided lesion targeting: a phantom study using HoloLens 2.增强现实技术可提高 CT 引导下病灶定位的程序效率并降低辐射剂量：使用 HoloLens 2 的体模研究。
Sci Rep. 2020 Oct 29;10(1):18620. doi: 10.1038/s41598-020-75676-4.
10
Irreversible Electroporation For Hepatocellular Carcinoma: Longer-Term Outcomes At A Single Centre.不可逆电穿孔治疗肝细胞癌：单中心的长期结果。
Cardiovasc Intervent Radiol. 2021 Feb;44(2):247-253. doi: 10.1007/s00270-020-02666-4. Epub 2020 Oct 13.